145 related articles for article (PubMed ID: 31389266)
1. Characteristics and circumstances of synthetic cannabinoid-related death.
Darke S; Duflou J; Farrell M; Peacock A; Lappin J
Clin Toxicol (Phila); 2020 May; 58(5):368-374. PubMed ID: 31389266
[No Abstract] [Full Text] [Related]
2. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA.
Tyndall JA; Gerona R; De Portu G; Trecki J; Elie MC; Lucas J; Slish J; Rand K; Bazydlo L; Holder M; Ryan MF; Myers P; Iovine N; Plourde M; Weeks E; Hanley JR; Endres G; St Germaine D; Dobrowolski PJ; Schwartz M
Clin Toxicol (Phila); 2015; 53(10):950-6. PubMed ID: 26555732
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and circumstances of death related to new psychoactive stimulants and hallucinogens in Australia.
Darke S; Duflou J; Peacock A; Farrell M; Lappin J
Drug Alcohol Depend; 2019 Nov; 204():107556. PubMed ID: 31546120
[TBL] [Abstract][Full Text] [Related]
4. Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA.
Angerer V; Jacobi S; Franz F; Auwärter V; Pietsch J
Forensic Sci Int; 2017 Dec; 281():e9-e15. PubMed ID: 29133010
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and circumstances of death related to gamma hydroxybutyrate (GHB).
Darke S; Peacock A; Duflou J; Farrell M; Lappin J
Clin Toxicol (Phila); 2020 Nov; 58(11):1028-1033. PubMed ID: 32068430
[No Abstract] [Full Text] [Related]
6. Characteristics and circumstances of death related to the self-administration of ketamine.
Darke S; Duflou J; Farrell M; Peacock A; Lappin J
Addiction; 2021 Feb; 116(2):339-345. PubMed ID: 32533718
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and circumstances of death related to buprenorphine toxicity in Australia.
Darke S; Duflou J; Larance B; Farrell M; Lappin J
Drug Alcohol Depend; 2021 Jan; 218():108360. PubMed ID: 33268226
[TBL] [Abstract][Full Text] [Related]
8. Functional effects of synthetic cannabinoids versus Δ
Schreiber S; Bader M; Lenchinski T; Meningher I; Rubovitch V; Katz Y; Cohen E; Gabet Y; Rotenberg M; Wolf EU; Pick CG
Addict Biol; 2019 May; 24(3):414-425. PubMed ID: 29423994
[TBL] [Abstract][Full Text] [Related]
9. Synthetic cannabinoids enhanced ethanol-induced motor impairments through reduction of central glutamate neurotransmission.
Funada M; Takebayashi-Ohsawa M; Tomiyama KI
Toxicol Appl Pharmacol; 2020 Dec; 408():115283. PubMed ID: 33068620
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the pharmacological properties of JWH-122 isomers and THJ-2201, RCS-4 and AB-CHMINACA in HEK293T cells and hippocampal neurons.
Costain WJ; Rasquinha I; Comas T; Hewitt M; Aylsworth A; Rouleau Y; Marleau V; Soo EC; Tauskela JS
Eur J Pharmacol; 2018 Mar; 823():96-104. PubMed ID: 29408093
[TBL] [Abstract][Full Text] [Related]
11. Aspects related to analysis and medico-legal assessment in the context of the presence of synthetic cannabinoids in biological material based on the example of AB-CHMINACA.
Romańczuk A; Rojek S; Kula K; Kłys M
Arch Med Sadowej Kryminol; 2018; 68(4):266-280. PubMed ID: 31025844
[TBL] [Abstract][Full Text] [Related]
12. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.
Hermanns-Clausen M; Müller D; Kithinji J; Angerer V; Franz F; Eyer F; Neurath H; Liebetrau G; Auwärter V
Clin Toxicol (Phila); 2018 Jun; 56(6):404-411. PubMed ID: 29072524
[TBL] [Abstract][Full Text] [Related]
13. Synthetic cannabinoid drug use as a cause or contributory cause of death.
Labay LM; Caruso JL; Gilson TP; Phipps RJ; Knight LD; Lemos NP; McIntyre IM; Stoppacher R; Tormos LM; Wiens AL; Williams E; Logan BK
Forensic Sci Int; 2016 Mar; 260():31-39. PubMed ID: 26795398
[TBL] [Abstract][Full Text] [Related]
14. AB-CHMINACA-induced sudden death from non-cardiogenic pulmonary edema.
Maeda H; Kikura-Hanajiri R; Kawamura M; Nagashima E; Yoshida KI
Clin Toxicol (Phila); 2018 Feb; 56(2):143-145. PubMed ID: 28707493
[TBL] [Abstract][Full Text] [Related]
15. Characteristics, toxicology and major organ pathology of deaths due to acute alcohol toxicity in Australia, 2011-2022.
Darke S; Duflou J; Peacock A; Chrzanowska A; Yuen WS; Farrell M; Lappin J
Drug Alcohol Rev; 2024 May; 43(4):937-945. PubMed ID: 38345860
[TBL] [Abstract][Full Text] [Related]
16. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015.
Abouchedid R; Hudson S; Thurtle N; Yamamoto T; Ho JH; Bailey G; Wood M; Sadones N; Stove CP; Dines A; Archer JRH; Wood DM; Dargan PI
Clin Toxicol (Phila); 2017 Jun; 55(5):338-345. PubMed ID: 28421836
[TBL] [Abstract][Full Text] [Related]
17. In vitro Phase I metabolism of indazole carboxamide synthetic cannabinoid MDMB-CHMINACA via human liver microsome incubation and high-resolution mass spectrometry.
Presley BC; Logan BK; Jansen-Varnum SA
Drug Test Anal; 2019 Aug; 11(8):1264-1276. PubMed ID: 31108568
[TBL] [Abstract][Full Text] [Related]
18. Rates, characteristics and manner of cannabis-related deaths in Australia 2000-2018.
Zahra E; Darke S; Degenhardt L; Campbell G
Drug Alcohol Depend; 2020 Jul; 212():108028. PubMed ID: 32370933
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, circumstances and toxicology of sudden or unnatural deaths involving very high-range alcohol concentrations.
Darke S; Duflou J; Torok M; Prolov T
Addiction; 2013 Aug; 108(8):1411-7. PubMed ID: 23560684
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and circumstances of volatile solvent misuse-related death in Australia, 2000-2021.
Darke S; Zahra E; Duflou J; Peacock A; Farrell M; Lappin J
Clin Toxicol (Phila); 2023 Apr; 61(4):260-265. PubMed ID: 37021728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
